Trajectory and risk factors for chemotherapy-induced nausea and vomiting in Asian patients with head and neck cancer

Chan, Alexandre; Shwe, Maung; Gan, Yanxiang; Yap, Kevin Yi-Lwern; Chew, Lita; Lim, Darren Wan-Teck

doi:10.1002/hed.23753

Cited by 9 publications

(15 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several publications provide insight into CINV characteristics and treatment in the Asia-Pacific region. 12 - 17 Observational studies in Malaysia, the Philippines, and Singapore indicate that nausea occurs more frequently than vomiting ( Table 1 ). However, the definitions for nausea and vomiting vary among studies, which makes comparison of the incidence difficult.…”

Section: Discussionmentioning

confidence: 99%

“…In a study conducted among patients with head and neck cancer in Singapore, single-day rather than multiday cisplatin therapy was associated with a 1.5-fold increase in the risk of nausea. 12 CINV experienced during previous chemotherapy. 12 , 14 , 18 In a multinational, prospective, observational study in patients who received highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC), previous CINV was a significant predictor of subsequent vomiting and clinically significant nausea and/or vomiting.…”

Section: Discussionmentioning

confidence: 99%

“… 12 CINV experienced during previous chemotherapy. 12 , 14 , 18 In a multinational, prospective, observational study in patients who received highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC), previous CINV was a significant predictor of subsequent vomiting and clinically significant nausea and/or vomiting. 18 Nonadherence to antiemetic therapy.…”

Section: Discussionmentioning

confidence: 99%

“…Among 235 patients treated with cisplatin-based regimens for head and neck cancer, concomitant radiotherapy was associated with nausea ( P = .022), and patients with an Eastern Cooperative Oncology Group score ≥ 1 were 2.4 times more likely to experience vomiting ( P = .046) than patients with a score of 0. 12 Female sex and younger than 50 years of age . The Pan Australasia Chemotherapy-Induced Emesis (PrACTICE) study conducted in Asian countries evaluated 648 patients who received HEC or MEC.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement

Chan

Abdullah

Ishak

et al. 2017

JGO

Self Cite

View full text Add to dashboard Cite

A meeting of regional experts was convened in Manila, Philippines, to develop a resource-stratified chemotherapy-induced nausea and vomiting (CINV) management guideline. In patients treated with highly emetogenic chemotherapy in general clinical settings, triple therapy with a serotonin (5-hydroxytryptamine-3 [5-HT3]) antagonist (preferably palonosetron), dexamethasone, and aprepitant is recommended for acute CINV prevention. In resource-restricted settings, triple therapy is still recommended, although a 5-HT3 antagonist other than palonosetron may be used. In both general and resource-restricted settings, dual therapy with dexamethasone (days 2 to 4) and aprepitant (days 2 to 3) is recommended to prevent delayed CINV. In patients treated with moderately emetogenic chemotherapy, dual therapy with a 5-HT3 antagonist, preferably palonosetron, and dexamethasone is recommended for acute CINV prevention in general settings; any 5-HT3 antagonist can be combined with dexamethasone in resource-restricted environments. In general settings, for the prevention of delayed CINV associated with moderately emetogenic chemotherapy, corticosteroid monotherapy on days 2 and 3 is recommended. If aprepitant is used on day 1, it should be continued on days 2 and 3. Prevention of delayed CINV with corticosteroids is preferred in resource-restricted settings. The expert panel also developed CINV management guidelines for anthracycline plus cyclophosphamide combination schedules, multiday cisplatin, and chemotherapy with low or minimal emetogenic potential, and its recommendations are detailed in this review. Overall, these regional guidelines provide definitive guidance for CINV management in general and resource-restricted settings. These consensus recommendations are anticipated to contribute to collaborative efforts to improve CINV management in Southeast Asia.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement

Chan

Abdullah

Ishak

et al. 2017

JGO

Self Cite

View full text Add to dashboard Cite

show abstract

The impact of induction and/or concurrent chemoradiotherapy on acute and late patient‐reported symptoms in oropharyngeal cancer: Application of a mixed‐model analysis of a prospective observational cohort registry

Dijk

Mohamed

Ferrarotto

et al. 2021

Cancer

View full text Add to dashboard Cite

BACKGROUND:The goal of this study was to comprehensively investigate the association of chemotherapy with trajectories of acute symptom development and late symptom recovery in patients with oropharyngeal cancer (OPC) by comparing symptom burden between induction chemotherapy followed by concurrent chemoradiotherapy (ICRT), concurrent chemo-radiotherapy (CRT), or radiotherapy (RT) alone. METHODS: Among a registry of 717 patients with OPC, the 28-item patient-reported MD Anderson Symptom Inventory-Head and Neck Module (MDASI-HN) symptoms were collected prospectively at baseline, weekly during RT, and 1.5, 3 to 6, 12, and 18 to 24 months after RT. The effect of the treatment regimen (ICRT, CRT, and RT alone) was examined with mixed-model analyses for the acute and late period. In the CRT cohort, the chemotherapy agent relationship with symptoms was investigated. RESULTS: Chemoradiation (ICRT/CRT) compared with RT alone resulted in significantly higher acute symptom scores in the majority of MDASI-HN symptoms (ie, 21 out of 28). No late symptom differences between treatment with or without chemotherapy were observed that were not attributable to ICRT. Nausea was lower for CRT with carboplatin than for CRT with cisplatin; cetuximab was associated with particularly higher scores for acute and late skin, mucositis, and 6 other symptoms. The addition of ICRT compared with CRT or RT alone was associated with a significant increase in numbness and shortness of breath. CONCLUSION: The addition of chemotherapy to definitive RT for OPC patients was associated with significantly worse acute symptom outcomes compared with RT alone, which seems to attenuate in the late posttreatment period. Moreover, induction chemotherapy was specifically associated with worse numbness and shortness of breath during and after treatment. Cancer 2021;0:1-12.

show abstract

A retrospective study on chemotherapy-induced nausea and vomiting in highly/moderately emetogenic chemotherapy: incidence and prescribing practice

Badarudin

Shah

Kassim

et al. 2022

Support Care Cancer

View full text Add to dashboard Cite

Trajectory and risk factors for chemotherapy-induced nausea and vomiting in Asian patients with head and neck cancer

Abstract: Although postchemotherapy vomiting is relatively well controlled in Asian patients with head and neck cancer, postchemotherapy nausea remains problematic in this population.

Cited by 9 publications

References 24 publications

Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement

Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement

The impact of induction and/or concurrent chemoradiotherapy on acute and late patient‐reported symptoms in oropharyngeal cancer: Application of a mixed‐model analysis of a prospective observational cohort registry

A retrospective study on chemotherapy-induced nausea and vomiting in highly/moderately emetogenic chemotherapy: incidence and prescribing practice

Contact Info

Product

Resources

About